Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis
- First Online:
- 584 Downloads
We used high-resolution peripheral quantitative computed tomography (HR-pQCT) to monitor changes in bone microarchitecture and strength at the distal radius and tibia associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis. Despite treatment-associated declines in total and cortical BMD, trabecular thinning and reduced trabecular bone volume, bone strength did not change significantly from baseline.
Teriparatide is an established anabolic therapy for osteoporosis; however, treatment effects at the distal radius are unclear. Therefore, we aimed to monitor changes in bone microarchitecture and estimated strength at the distal radius and tibia in osteoporotic postmenopausal women.
We used high-resolution peripheral quantitative computed tomography (Scanco Medical, Switzerland) to perform a standard three-dimensional morphological analysis of the distal radius and tibia in 11 osteoporotic postmenopausal women (mean age, 68.7 ± 12.7 years) at baseline, 6, 12, and 18 months after initiation of 20 μg/day of teriparatide. Ten of the women received bisphosphonate therapy prior to starting on teriparatide. In addition to the standard analysis, we quantified cortical bone mineral density (BMD), porosity, and thickness using an automated segmentation procedure and estimated bone strength (ultimate stress) using finite element analysis.
After 18 months, we observed a decrease in total BMD (p = 0.03) at the distal radius and a decrease in cortical BMD at the distal radius (p = 0.05) and tibia (p = 0.01). The declines in cortical BMD were associated with trends for increased cortical porosity at both sites. At the distal radius, 18 months of teriparatide treatment was also associated with trabecular thinning (p = 0.009) and reduced trabecular bone volume ratio (p = 0.08). We observed similar trends at the distal tibia. Despite these changes in bone quality, bone strength was maintained over the 18-month follow-up.
The observed changes in cortical bone structure are consistent with the effects of parathyroid hormone on intracortical bone remodeling. Controlled trials involving larger sample sizes are required to confirm the effects of teriparatide therapy on trabecular and cortical microarchitecture in the peripheral skeleton.
KeywordsBone microarchitecture Bone strength HR-pQCT Osteoporosis Teriparatide
- 2.Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441CrossRefPubMedGoogle Scholar
- 5.Graeff C, Chevalier Y, Charlebois M, Varga P, Pahr D, Nickelsen TN, Morlock MM, Gluer CC, Zysset PK (2009) Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: results from the EUROFORS study. J Bone Miner Res 24:1672–1680CrossRefPubMedGoogle Scholar
- 6.Borggrefe J, Graeff C, Nickelsen TN, Marin F, Gluer CC (2010) Quantitative computed tomography assessment of the effects of 24 months of teriparatide treatment on 3-D femoral neck bone distribution, geometry and bone strength: results from the EUROFORS study. J Bone Miner Res 25:472–481.CrossRefPubMedGoogle Scholar
- 8.Kirmani S, Holets M, Khosla S (2007) Effects of one year treatment with PTH(1-34) on bone microstructure at the ultradistal radius. J Bone Miner Res 22:S24Google Scholar
- 9.Thomas T, Alexandre C, van Rietbergen B, Reuter N, Zouch M, Vico L (2009) Teriparatide effects on bone markers and bone microarchitecture in osteoporotic women: 18-month evaluation by high resolution pQCT. J Bone Miner Res Suppl 1. Available at: http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=38c472aa-6fef-4f6b-81a6-4f37842c8fe3. Accessed on: 30 Sep 2009
- 10.Bogado C, Zanchetta J, Zhou H, Dempster D, Kohler T, Muller R, Fosser C, Tuthill T, Brown T, Thompson D, Fryburg D, Keaveny T, Masiukiewicz U (2009) Temporal effects of teriparatide on bone microarchitecture assesed by high resolution peripheral quantitative computerized tomography and paired bone biopsies in postmenopausal women with osteoporosis. J Bone Miner Res 24. Available at: http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=8024c8014d-c8022f8022-8024a8020d-bd8023c-0584c8085b8091ad. Accessed on: 8 Dec 2009
- 20.Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM (2001) Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 16:157–165CrossRefPubMedGoogle Scholar
- 22.Misof BM, Roschger P, Cosman F, Kurland ES, Tesch W, Messmer P, Dempster DW, Nieves J, Shane E, Fratzl P, Klaushofer K, Bilezikian J, Lindsay R (2003) Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab 88:1150–1156CrossRefPubMedGoogle Scholar
- 23.Hanley DA, Watson PM, Hodsman AB, Dempster DW (2008) Pharmacologic mechanisms of therapeutics: parathyroid hormone. In: Bilezikian JP, Raisz LG, Martin TJ (eds) Principles of bone biology, 3rd edn. Elsevier, Amsterdam, pp 1661–1695Google Scholar